Molecularly Aided Stratification for Tumor Eradication Research

German Cancer Research Center10,000 enrolled

Overview

NCT/DKFZ/DKTK MASTER is a prospective, continuously recruiting, multicenter observational study for biology-guided stratification of adults with rare cancers, including rare subtypes of common entities, using comprehensive molecular profiling, and clinical decision-making in a multidisciplinary molecular tumor board.

Study Type

OBSERVATIONAL

Enrollment

10,000

Conditions

Rare Cancers Multiomics

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: Rare cancer (Incidence \<6/100,000 persons/year) or Rare subtype of a more common entity (case-by-case decision; example: pancreatic ductal adenocarcinoma without KRAS mutation) Metastatic and/or locally advanced cancer with no curative therapy option and indication for systemic therapy Exclusion Criteria: Severe neurological or psychiatric disorder interfering with the ability to give oral and written informed consent

Locations (1)

German Cancer Research Center

Heidelberg, Germany

RECRUITING

Outcomes

Primary Outcomes

progression free survival

Time period of progression survival from date of multiomics analysis

Time frame: 5 years

overall survival

time period of survival from date of diagnosis

Time frame: 10 years

Secondary Outcomes

response to antitumor treatment

response according to RECIST v.1.1 criteria to antitumor treatment applied after multiomics analysis

Time frame: 5 months

Central Contacts

Richard F Schlenk, M.D.

CONTACT

+49 6221 richard.schlenk@nct-heidelberg.de

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.